Diabetes Mellitus Clinical Trial
Official title:
Pilot Study of a Primary Care Hypoglycemia Prevention Program
This is a single site, pre-post pilot study. The objective is to evaluate the acceptability and feasibility of a primary care hypoglycemia prevention program for patients taking hypoglycemia-causing medications. The study will also evaluate relevant process outcomes and clinical outcomes for refining the intervention and planning for a larger efficacy trial.
Status | Recruiting |
Enrollment | 35 |
Est. completion date | April 14, 2026 |
Est. primary completion date | April 14, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion criteria for patients: - Age 18 years or older - Diabetes mellitus by electronic health record review - Treatment with any of the following medication classes: insulin, sulfonylureas, meglitinides - Community dwelling (not residing in long-term care or a skilled nursing facility) - Receiving primary care from a participating primary care provider at Johns Hopkins Internal Medicine at Green Spring Station - The patient's primary care provider approves their participation Exclusion criteria for patients: - Significant cognitive impairment or dementia - Receiving hospice or end of life care - Any other serious illness or condition not compatible with participation as determined by the investigators - Planning to leave area prior to end of study - Investigator discretion Exclusion Criteria for continuous glucose monitoring (not required for study participation): - History of allergic skin reaction to adhesive - Implantable pacemaker Inclusion criteria for primary care providers: - Practicing at Johns Hopkins Internal Medicine Green Spring Station Exclusion criteria for primary care providers: - Planning to leave their position prior to end of study - Not serving as primary care provider for any included patient Inclusion criteria for clinic staff: - Participating in check-in at Johns Hopkins Internal Medicine Green Spring Station Exclusion criteria for clinic staff - Planning to leave their position prior to end of study |
Country | Name | City | State |
---|---|---|---|
United States | Johns Hopkins University School of Medicine | Baltimore | Maryland |
Lead Sponsor | Collaborator |
---|---|
Johns Hopkins University | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Intervention coherence (patients) | Mean score for intervention coherence on patient intervention evaluation survey (developed for this study, range 1-strongly disagree, to 5-strongly agree) | Immediately after the intervention | |
Other | Opportunity costs (patients) | Mean score for opportunity costs on patient intervention evaluation survey (developed for this study, range 1-strongly disagree, to 5-strongly agree) | Immediately after the intervention | |
Other | Ethicality (patients) | Mean score for ethicality on patient intervention evaluation survey (developed for this study, range 1-very unfair, to 5-very fair) | Immediately after the intervention | |
Other | Affective attitude (patients) | Mean score for affective attitude on patient intervention evaluation survey (developed for this study, range 1-very uncomfortable, to 5-very comfortable) | Immediately after the intervention | |
Other | Burden (patients) | Mean score for burden on patient intervention evaluation survey (developed for this study, range 1-no effort at all, to 5-huge effort) | Immediately after the intervention | |
Other | Self-efficacy (patients) | Mean score for self-efficacy on patient intervention evaluation survey (developed for this study, range 1-very un-confident, to 5-very confident) | Immediately after the intervention | |
Other | Perceived effectiveness (primary care providers) | Mean score for perceived effectiveness on primary care provider intervention evaluation survey (developed for this study, range 1-strongly disagree, to 5-strongly agree) | Immediately after the intervention | |
Other | Intervention coherence (primary care providers) | Mean score for intervention coherence on primary care provider intervention evaluation survey (developed for this study, range 1-strongly disagree, to 5-strongly agree) | Immediately after the intervention | |
Other | Opportunity costs (primary care providers) | Mean score for opportunity costs on primary care provider intervention evaluation survey (developed for this study, range 1-strongly disagree, to 5-strongly agree) | Immediately after the intervention | |
Other | Affective attitude (primary care providers) | Mean score for affective attitude on primary care provider intervention evaluation survey (developed for this study, range 1-very uncomfortable, to 5-very comfortable) | Immediately after the intervention | |
Other | Burden (primary care providers) | Mean score for burden on primary care provider intervention evaluation survey (developed for this study, range 1-no effort at all, to 5-huge effort) | Immediately after the intervention | |
Other | Self-efficacy (primary care providers) | Mean score for self-efficacy on primary care provider intervention evaluation survey (developed for this study, range 1-Very unconfident, to 5-very confident) | Immediately after the intervention | |
Other | Burden (clinic staff) | Mean score for burden on clinic staff intervention evaluation survey (developed for this study, range 1-no effort at all, to 5-huge effort) | Immediately after the intervention | |
Other | Opportunity costs (clinic staff) | Mean score for opportunity costs on clinic staff intervention evaluation survey (developed for this study, range 1-strongly disagree, to 5-strongly agree) | Immediately after the intervention | |
Other | Recruitment rate | % of eligible participants who consented to participate | Immediately after the intervention | |
Other | Retention rate for second clinic visit | % of participants who completed two clinic visits | Immediately after the intervention | |
Other | Continuous glucose monitoring (CGM) completion | % of participants who completed CGM measurements | Immediately after the final CGM measurement (4-12 weeks after the intervention) | |
Other | Continuous glucose monitoring (CGM) wear time | Mean days with complete CGM data | Immediately after the final CGM measurement (4-12 weeks after the intervention) | |
Other | Time needed to complete patient hypoglycemia profile | Mean completion time (minutes) for patient hypoglycemia profile | Immediately after completion of intervention clinic visit | |
Other | Duration of clinical visit | Change from baseline in mean duration of clinic visit (minutes) | Change from baseline to immediately after completion of intervention clinic visit | |
Other | Patient completion of hypoglycemia assessment | Completion rate overall and for individual items | Immediately after completion of intervention clinic visit | |
Other | Primary care provider use of provider hypoglycemia toolkit | Rate of toolkit use overall and for individual tools | Immediately after completion of intervention clinic visit | |
Other | Patient hypoglycemia burden on continuous glucose monitoring (CGM) | Change from baseline in mean minutes per day with glucose <70 mg/dl and <54 mg/dl | Baseline to post-intervention up to 12 weeks | |
Other | Patient time below range on continuous glucose monitoring (CGM) | Change from baseline in % time with glucose <70 mg/dl | Baseline to post-intervention up to 12 weeks | |
Other | Patient time above range on continuous glucose monitoring (CGM) | Change from baseline in % time with glucose >180 mg/dl | Baseline to post-intervention up to 12 weeks | |
Other | Patient mean glucose on continuous glucose monitoring (CGM) | Change from baseline in mean glucose | Baseline to post-intervention up to 12 weeks | |
Other | Patient satisfaction with care | Change from baseline in mean score on The Patient Satisfaction Questionnaire Short Form (PSQ-18), range 1 (lowest satisfaction) to 5 (highest satisfaction) in 7 domains | Change from baseline to immediately after the intervention | |
Other | Patient activation | Change from baseline in mean score on Patient Activation Measure (PAM 10), range 0 (lowest activation) to 100 (highest activation) | Change from baseline to immediately after the intervention | |
Other | Patient self-reported hypoglycemic events | Change from baseline in frequency of level 1, level 2, and level 3 hypoglycemia events on hypoglycemia history survey | Change from baseline to 4-12 weeks after the intervention | |
Other | Changes to hypoglycemia-causing medications | % of patients with changes in diabetes medications (dose increase, decrease, stop, switch, initiate) | Change from baseline to immediately after the intervention | |
Other | Glucagon prescription | % of patients with active glucagon prescription | Change from baseline to immediately after the intervention | |
Other | Continuous glucose monitoring (CGM) prescription | Change from baseline in frequency of CGM prescription | Change from baseline to immediately after the intervention | |
Other | Change in Frequency of Referrals to Diabetes Self Management Training (DSMT) | Change from baseline in frequency of DSMT referral | Change from baseline to immediately after the intervention | |
Other | Frequency of hypoglycemia history discussions | Frequency and content of hypoglycemia history discussion by audio-recording | Change from baseline to immediately after the intervention | |
Other | Frequency of Hypoglycemia anticipatory guidance discussions | Frequency, content, and accuracy of hypoglycemia anticipatory guidance | Change from baseline to immediately after the intervention | |
Other | Frequency of Medication adherence discussions | Frequency and content of discussions of adherence to diabetes medications | Change from baseline to immediately after the intervention | |
Primary | Overall acceptability to patients | Mean score for overall acceptability on patient intervention evaluation survey (developed for this study, range 1-completely unacceptable, to 5-completely acceptable) | Immediately after the intervention | |
Primary | Overall acceptability to primary care providers | Mean score for overall acceptability on primary care provider intervention evaluation survey (developed for this study, range 1-completely unacceptable, to 5-completely acceptable) | Immediately after the intervention | |
Primary | Overall acceptability to clinic staff | Mean score for overall acceptability on clinic staff intervention evaluation survey (developed for this study, range 1-completely unacceptable, to 5-completely acceptable) | Immediately after the intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |